Trial · NCT02193152
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
NCT02193152, Phase 2, Terminated, Washington University School of Medicine; results first posted 2020-07-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib in Molecularly Selected Patients With Advanced NSCLC. Trials, record NCT02193152. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02193152
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib in Molecularly Selected Patients With Advanced NSCLC
- NCT number
- NCT02193152
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 16 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
- Interventions
- Pazopanib
- First posted
- 2014-07-17
- Last updated
- 2020-07-14
- Results first posted
- 2020-07-14
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate | Until the end of treatment (median length of treatment=85.5 days (full range 25-334 days) | * Participants should be re-evaluated for response 8 weeks after initiation of pazopanib and then every 8 weeks thereafter. In addition to a baseline scan, confirmatory scans should also be obtained not less than 4 weeks following initial documentation of objective response. * Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) \[Eur J Ca 45:228-247, 2009\]. * Response rate is the percentage of participants with a complete or partial response * Complete response=Disappearance of all target and non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). * Partial response=At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters |
| Primary | Progression-free Survival (PFS) | Until progressive disease or death (median follow-up 174 days, full range 41 days-545 days) | * Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. There is no limit on following for progression-free survival besides death of the participant. * Progressive disease=At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). |
| Secondary | Outcomes Associated With Specific Mutations | Until time of death (an expected average of 8 months) | * Participants are followed until death. * All participants will undergo next generation sequencing prior to enrollment into the study. * Initial predictors are the mutations in VEGFR or PDGFR, but sequencing will be used to evaluate for other predictors as well. |
| Secondary | Mutational Predictors for Extreme Responders | Until end of treatment (an expected average of 8 months) | -Whole exome and transcriptome sequencing will be performed in 10 participants, including 4 to 6 responders and 4 to 6 non-responders in order to identify the predictors for benefit. |
| Secondary | Mechanisms of Secondary Resistance. | Until the time of progressive disease (an expected average of 8 months) | -Participants will also undergo next generation sequencing at the time of progression in an attempt to identify the mechanisms for secondary resistance. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate | Until the end of treatment (median length of treatment=85.5 days (full range 25-334 days) | 4 participants were not evaluable for this outcome measure because they were removed from treatment prior to the re-evaluation response at 8 weeks | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Progression-free Survival (PFS) | Until progressive disease or death (median follow-up 174 days, full range 41 days-545 days) | weeks | MEDIAN | |
| SECONDARY | Outcomes Associated With Specific Mutations | Until time of death (an expected average of 8 months) | The data was not collected for this outcome measure. | ||
| SECONDARY | Mutational Predictors for Extreme Responders | Until end of treatment (an expected average of 8 months) | The data was not collected for this outcome measure. | ||
| SECONDARY | Mechanisms of Secondary Resistance. | Until the time of progressive disease (an expected average of 8 months) | The data was not collected for this outcome measure. |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate | Treatment: Pazopanib | 2 | Participants | ||
| Progression-free Survival (PFS) | Treatment: Pazopanib | 13.25 | Full Range 3.5 to 47.8 | weeks |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment: Pazopanib | 16 | |
| Overall Study | COMPLETED | Treatment: Pazopanib | 16 | |
| Overall Study | NOT COMPLETED | Treatment: Pazopanib | 0 |
Source ClinicalTrials.gov
Adverse events77
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment: Pazopanib | 1 | 16 | |
| other | Tachycardia | Cardiac disorders | Treatment: Pazopanib | 1 | 16 | |
| other | Visual changes | Eye disorders | Treatment: Pazopanib | 1 | 16 | |
| other | Hypothryoidism | Endocrine disorders | Treatment: Pazopanib | 3 | 16 | |
| other | Abdominal pain | Gastrointestinal disorders | Treatment: Pazopanib | 4 | 16 | |
| other | Constipation | Gastrointestinal disorders | Treatment: Pazopanib | 11 | 16 | |
| other | Diarrhea | Gastrointestinal disorders | Treatment: Pazopanib | 5 | 16 | |
| other | Dyspepsia | Gastrointestinal disorders | Treatment: Pazopanib | 7 | 16 | |
| other | Gingival pain | Gastrointestinal disorders | Treatment: Pazopanib | 1 | 16 | |
| other | Mucositis oral | Gastrointestinal disorders | Treatment: Pazopanib | 5 | 16 |
1 to 10 of 77Source ClinicalTrials.gov
See all 77 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment: Pazopanib | 14 | 16 |
| Total, other adverse events | Treatment: Pazopanib | 16 | 16 |
| Total, serious adverse events | Treatment: Pazopanib | 8 | 16 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02193152
GET https://conductscience.org/api/trials/v1/NCT02193152/events?page=2